Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Provectus Pharmaceuticals ( (PVCT) ) is now available.
On January 30, 2026, Provectus Biopharmaceuticals, Inc. amended the terms of its Series D and Series D-1 Convertible Preferred Stock by filing certificates of amendment in Delaware, a move approved by its board and a special committee of independent directors. The amendments extended the automatic conversion date of these preferred shares into common stock from June 20, 2026, to December 31, 2028, effectively delaying the scheduled conversion and thereby adjusting the company’s capital structure and timing of potential dilution for existing common shareholders and preferred stock investors.
More about Provectus Pharmaceuticals
Provectus Biopharmaceuticals, Inc. is a biopharmaceutical company, operating in the life sciences sector and focused on developing pharmaceutical products, with its capital structure including various series of convertible preferred stock and common stock.
Average Trading Volume: 282,293
Technical Sentiment Signal: Sell
Current Market Cap: $21.43M
Find detailed analytics on PVCT stock on TipRanks’ Stock Analysis page.